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MEASUREMENT PROPERTIES OF THE SPANISH VERSION OF THE PEDIATRIC
PROMIS FATIGUE ITEM BANK
Lai JS, Correia H, Cella D
Northwestern University, Chicago, IL, USA
OBJECTIVES: Fatigue is common among children with chronic conditions. In order
to compare results across languages, a requirement for many clinical trials, one
must ensure measurement is not biased by language. This paper reports the psy-
chometric properties of the Spanish version of the pediatric PROMIS (Patient Re-
ported Outcomes Measurement Information System) fatigue item bank (Spanish-
PedsFIB). Developed via a collaborative effort funded by the National Institutes of
Health of the United States, PROMIS allows for comparisons across domains and
conditions for both adults and children.METHODS: Data from 605 Spanish-speak-
ing participants, recruited from a US general population panel, were analyzed.
Average age was 12.3 years and 45.5% were female. Participants completed the
23-item Spanish-PedsFIB, translated from English via a rigorous methodology (2
forward translations, 1 reconciliation, 1 back-translation, review by bilingual ex-
perts, and cognitive debriefing). Psychometric analyses included confirmatory fac-
tor analysis (CFA) to evaluate unidimensionality (criteria: comparative fit index CFI
 0.95; RMSEA  0.08, MI 10), residual correlations to evaluate local dependency
(criterion: r0.15), S-G2 and S-2 to evaluate item fit (criterion: p 0.01). Graded
Response Model as implemented in MULTILOG was used to estimate item param-
eters, and LORDIF (R freeware) was used to evaluate differential item functioning
between the Spanish and English versions (criteria: p.01). RESULTS: CFA results
supported unidimensionality of these 23 items: CFI0.995, RMSEA0.056, residual
correlation absolute values ranged from 0 to 0.05, and R2 ranged from 0.69 and 0.87.
One item had poor fit with p0.0041 and 0.0093 for S-G2 and S-2, respectively. Six
items (measuring more severe fatigue) exhibited significant DIF. Correlation be-
tween scores with and without DIF candidate items was 0.97. CONCLUSIONS: Ex-
cellent psychometric properties of the Spanish version of Spanish-PedsFIB were
evidenced. Comparative studies can be conducted using the English and Spanish
versions. Currently, more translations are in progress.
RESEARCH ON METHODS - Statistical Methods
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SURVIVAL CURVE CONVERGENCES AND CROSSING: A THREAT TO VALIDITY OF
META-ANALYSIS?
Kristiansen IS
University of Oslo, Oslo, Norway
OBJECTIVES:When data from survival analysis are summarized in meta analysis,
they are usually based on the number of events at the end of the study. This will
bias the estimates of differences in survival unless the relative hazards are rela-
tively constant (the proportional hazards assumption). The aimof this studywas to
explore this assumption by estimating the frequency of convergences and cross-
ings of survival curves. METHODS: We reviewed all publications in Annals of In-
ternal Medicine, British Medical Journal, JAMA, New England Journal of Medicine
(NEJM) and The Lancet for 2007 and identified studies that included survival
graphs. We extracted the following data from included studies: type of disease,
type of exposure, sample size and number of events, maximum follow-up time,
number and timing of survival curve convergences and crossings, andwhether Cox
regression and log-rank tests had been performed. RESULTS: Among 175 included
studies, 35% had survival curve convergences and 47% crossings. 38% of the cross-
ings occurred later than halfway through the study (40% for convergences). The
proportion of crossings by type of disease was 46% for cardiovascular disease, 38%
for cancer and 53% for other diseases. Among studieswith survival curve crossings,
Cox regression was performed in 66% and logrank-test in 70% of the studies. Only
31% of all the studies reported testing for proportional hazards when Cox regres-
sion had been employed. CONCLUSIONS: Survival curve convergences and cross-
ings are common in medical research. Effectiveness estimates based on end of
study resultswill likely be biased unless convergences and crossings are accounted
for, and this bias will carry over tometa analyses of individual studies. Researchers
frequently employ Cox modeling when the proportional hazard assumption is not
met or use log rank tests when other test would be more appropriate.
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APPLYING STRATIFICATION ON TIME TO OVERCOME TIME-VARYING
COVARIATES EFFECTS IN COX PROPORTIONAL HAZARDS MODELS
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OBJECTIVES: Cox proportional hazards models are widely used in the analysis of
survival data to explain the effects of prognostic factors on survival time. The
model assumes proportionality of prognostic factors over time. Prognostic factor
values, however, are often not constant over time, causing time-varying covariate
(TVC) effects. In order to overcome this problem, a helpfulmethod is to incorporate
stratification on time. This study estimates the survival of chronic renal failure
(CRF) patients using the abovemethod.METHODS:This analysis was conducted on
data from 145 patients in a Malaysian government hospital. The assumption of
proportionality was analyzed by using log cumulative hazards curves plotted
against log time (log-minus-log) and Schoenfeld residuals and scaled Schoenfeld
partial residuals. TVC was analyzed by the interactions of prognostic factors with
log time. Violation of the proportionality assumption was overcome by stratifica-
tion on time of the prognostic factors. RESULTS: Median survival time of CRF pa-
tients in the study was estimated at 4.5 years. The significant prognostic factors
were ex-smokers (p0.043), current smokers (p0.035) and post-renal failure hy-
pertension (p0.054). The proportionality assumption was violated in the ex-
smokers’ factor as shown by log-minus-log and Schoenfeld residuals and scaled
Schoenfeld partial residuals. Stratification on time at 0.8 years was applied to cor-
rect the problem. CONCLUSIONS: Survival analysis in this study using the Cox
proportional hazards model was affected by the TVC effect on the ex-smokers as a
prognostic factor. Stratification on time was able to overcome this problem.
RESEARCH ON METHODS - Conceptual Papers
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MULTIPLE CRITERIA DECISION ANALYSIS FOR HEALTH TECHNOLOGY
ASSESSMENT
Thokala P
University of Sheffield, Sheffield, UK
OBJECTIVES: This paper will discuss the different methods of multi criteria deci-
sion analysis (MCDA) that could be used in health technology assessment (HTA)
and their relative merits.Description: The current practice of health technology
appraisals is based on the incremental cost-effectiveness ratio (ICER) i.e. the incre-
mental cost per quality adjusted life year (QALY) gained by recipients of treatment.
Even though other factors (e.g. severity, life saving, etc) are considered along with
ICERs, there is concern that its approach may fail to capture other important
sources of value. METHODS: MCDA is aimed at supporting decision makers faced
with evaluating alternatives taking into account multiple, and often conflictive,
criteria in an explicit manner. An overview of MCDA is provided and is compared
against the current health technology appraisal processes. A number of important
questions are addressed to identify themost appropriateMCDAmethod thatmight
be used to support decision making. For example, what criteria should be incorpo-
rated? Whose weights should be used and how to elicit them? How to incorporate
uncertainty into the MCDA process? How do we consider the value of displaced
technologies? What should the ‘basic’ cost-effectiveness threshold be? How do we
estimate it? This paper will discuss these questions, outline and assess method-
ological issues that would be raised by the use of MCDA in health technology
assessment (HTA). RESULTS:Most of the proposed MCDA approaches in literature
use the same technique (weighted sum approach), however, more flexible ap-
proaches are available that are relevant to health technology appraisal and value
based pricing (VBP). CONCLUSIONS: There are general practical issues that might
arise from using this MCDA approach in the HTA process and further research
needs to be performed to address the issues identified in order to ensure the suc-
cess of this MCDA technique in the appraisal process.
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ASSESSMENT OF NEW DRUG REIMBURSEMENT AND PRICING APPLICATION TO
TAIWAN NATIONAL HEALTH INSURANCE (NHI)
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The Principles on Drug Reimbursement Price Approval(PDRPA) is the basis for pricing
new pharmaceuticals for NHI reimbursement in Taiwan. PDRPA describes the
scope of comparative treatments and defines the 3Categories of new drug as: 1
(breakthrough); 2A (moderate improvement); and 2B (similar) based on the com-
parative effectiveness of new drug to the current therapies, which links to the
decision of pricing method used. The selection of comparator is crucial in technol-
ogy assessment and has profound influence on the pricing decision. Hereby we
explicitly describe the selection rules and roles of comparator(s). To sort out the
rationale of comparator selection, the following 8 features of a comparator are
considered: 1) indication(s) approved by department of health Taiwan; 2) associ-
ated reimbursement guidance; 3) ATC (Anatomical Therapeutic Chemical) classi-
fication; 4) clinical guidance of using the comparator on treating target disease by
new drug; 5) comparative evidence such as head-to-head trial or indirect compar-
ison; 6) NHI reimburse price; 7) prices of comparator in the 10 reference countries;
and 8) recent utilization in NHI. Clinical relevant and appropriateness are the pri-
ority of comparator(s) selection. To be qualified as class 1 or 2A new drug, the
currently best therapy should be used as comparator. Then one of the 6 pricing
methodswill be chosen to decide the reimbursement price of the new drug, with or
without reimbursement guidance on using the new drug; and/or the decision to
initiate price-volume agreement or (financial) risk sharing negotiation with the
pharmaceutical company. Five possible roles of the comparator(s) would play in
the assessment: 1) to justify the comparative effectiveness to the new drug; 2) to
calculate the price of new drug; 3) to evaluate the net budget impact; 4) as reference
setting for reimbursement guidance; and 5) be used in pharmacoeconomic study.
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PHARMACOECONOMIC ANALYSIS EMBEDDED IN THE DRUG DEVELOPMENT
PROCESS
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OBJECTIVES: Pharmaceutical companies are under pressure to assess the eco-
nomic value of their pipeline assets. Pharmacoeconomic (PE) analysis can be em-
ployed to improve the decision-making process by providing robust estimations of
comparative economic value before the commercial launch. Clinical and Compar-
ative Economic Value (CCEV)methodology, has been developed to provide insights
into the sources of economic values of innovative products (drugs, devices, ser-
vices) to inform critical decisions across the product life cycle.METHODS: Amulti-
state disease model is developed to simulate the major clinical events in the dis-
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